Anticoagulants, Antiplatelets, and Thrombolytics

Volume 663 of the series Methods in Molecular Biology pp 109-132


Heparin and Low-Molecular Weight Heparins in Thrombosis and Beyond

  • Shaker A. MousaAffiliated withPharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences

* Final gross prices may vary according to local VAT.

Get Access


Heparin and its improved version, low-molecular weight heparin (LMWH), are known to exert polypharmacological effects at various levels. Early studies focused on the plasma anti-Xa and anti-IIa pharmacodynamics of different LMWHs. Other important pharmacodynamic parameters for heparin and LMWH, including effects on vascular tissue factor pathway inhibitor (TFPI) release, inhibition of inflammation through NFκB, inhibition of key matrix-degrading enzymes, selectin modulation, inhibition of platelet–cancer cell interactions, and inflammatory cell adhesion, help explain the diverse clinical impact of this class of agents in thrombosis and beyond.

Key words

Heparin low-molecular weight heparin tissue factor pathway inhibitor angiogenesis tumor growth metastasis asthma inflammation